fluorouracil has been researched along with everolimus in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 31 (86.11) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Collingridge, D | 1 |
| Mehta, SP | 1 |
| Eriksson, B | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Lee, J; Lee, KH; Oh, DY; Song, SH; Yoon, YK | 1 |
| Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS | 1 |
| Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW | 1 |
| Breitenbuecher, F; Hähnel, PS; Herbertz, S; Kasper, S; Markova, B; Schuler, M | 1 |
| Cai, XJ; Cong, W; Hong, DF; Xin, Y; Zhou, N | 1 |
| Chang, HM; Kang, YK; Kim, TW; Lee, C; Lee, HJ; Lee, JL; Park, YS; Ryoo, BY; Ryu, MH; Yoon, DH | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW | 1 |
| Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Imai, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Akcakanat, A; Brewster, AM; Chen, H; Crawford, D; Do, KA; Dryden, MJ; Flores, P; Giordano, SH; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Litton, JK; Liu, S; Meric-Bernstam, F; Mills, GB; Moore, J; Moulder-Thompson, S; Murray, JL; Palla, SL; Pusztai, L; Sahin, A; Symmans, WF; Tarco, E; Valero, V | 1 |
| Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY | 1 |
| Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG | 1 |
| Chao, Y; Chen, LT; Cheng, AL; Hsu, C; Li, CP; Lin, YL; Lin, ZZ; Shen, YC; Su, WC; Yeh, KH; Yen, CJ | 1 |
| Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV | 1 |
| Hoffmann, OI; Ilmberger, C; Jauch, KW; Joka, M; Magosch, S; Mayer, B | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW | 1 |
| Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C | 1 |
| Aristizabal Prada, ET; Auernhammer, CJ; Maurer, J; Nölting, S; Spoettl, G | 1 |
| Bertolini, F; Cascinu, S; Conte, P; Gelsomino, F; Luppi, G; Manco, G; Meduri, B; Pettorelli, E; Reggiani Bonetti, L; Spallanzani, A | 1 |
| Aristizabal Prada, ET; Auernhammer, C; Maurer, J; Nölting, S; Orth, M; Spöttl, G | 1 |
| Albers, AE; Fichtner, I; Hoffmann, J; Keilholz, U; Klinghammer, K; Leser, U; Otto, R; Raguse, JD; Tinhofer, I | 1 |
| Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N | 1 |
| Jia, QA; Kadel, D; Zhang, QB; Zhang, XF; Zhang, Y | 1 |
| Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J | 1 |
| Nguyen, HT; Poole, AC; Sponheim, J; Thiis-Evensen, E | 1 |
| Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC | 1 |
| Barkovskaya, A; Briem, E; Der, CJ; Engebraaten, O; Goodwin, CM; Gudjonsson, T; Hilmarsdottir, B; Maelandsmo, GM; Moestue, SA; Pettersen, S; Prasmickaite, L; Seip, K; Stalnecker, C | 1 |
| Chen, J; Deng, H; He, Z; Jin, L; Liu, J; Nie, Y; Rao, N; Su, F; Wu, W; Yang, Y; Yao, Y | 1 |
3 review(s) available for fluorouracil and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
16 trial(s) available for fluorouracil and everolimus
| Article | Year |
|---|---|
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Dropouts; Platinum Compounds; Sirolimus; Stomach Neoplasms; Treatment Outcome | 2012 |
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult | 2013 |
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Early Termination of Clinical Trials; Everolimus; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Severity of Illness Index; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pilot Projects; Sirolimus; Stomach Neoplasms; Taiwan; Treatment Outcome | 2014 |
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2015 |
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Everolimus; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Stomach Neoplasms; Treatment Outcome | 2016 |
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Treatment Outcome | 2017 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden | 2017 |
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Everolimus; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxaliplatin; Prognosis; Survival Rate; Tissue Distribution; Young Adult | 2019 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2021 |
17 other study(ies) available for fluorouracil and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Everolimus; Fluorouracil; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Protein Serine-Threonine Kinases; Sirolimus; Stomach Neoplasms; Thymidylate Synthase; TOR Serine-Threonine Kinases | 2010 |
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Flow Cytometry; Fluorouracil; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung; Lung Neoplasms; Pemetrexed; Sirolimus; Thymidylate Synthase; Time Factors; TOR Serine-Threonine Kinases | 2012 |
[RAD001 reverses radio-resistance and exerts synergistic tumor inhibition with 5-fluorouracil].
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Everolimus; Fluorouracil; Humans; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A | 2011 |
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gene Amplification; Humans; Paclitaxel; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Trastuzumab | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib | 2015 |
Impact of the spheroid model complexity on drug response.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cetuximab; Coculture Techniques; Everolimus; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Spheroids, Cellular; Stromal Cells; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Vorinostat | 2015 |
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Topics: Aminopyridines; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Fluorouracil; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; Purines; Time Factors | 2018 |
The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Everolimus; Fluorouracil; Gamma Rays; Humans; Neuroendocrine Cells; Neuroendocrine Tumors; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Proto-Oncogene Proteins c-akt; Pyrimidines; Radiotherapy, Adjuvant; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Everolimus; Fluorouracil; Gene Expression; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Mice; Mice, Inbred NOD; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Everolimus; Fluorouracil; G1 Phase; Humans; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Morpholines; Treatment Outcome; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Everolimus; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prognosis; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Streptozocin; Survival Rate; Time Factors | 2020 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Streptozocin; Temozolomide; Treatment Outcome; Young Adult | 2022 |
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen.
Topics: Antineoplastic Agents; Cell Proliferation; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; Everolimus; Female; Fluorouracil; Humans; Loss of Function Mutation; Phenotype; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |